Humanin vs Vilon.

Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP), one of the first members of a class of small peptides encoded by short open reading frames within the mitochondrial genome rather than the nuclear genome. Its coding sequence sits inside the mitochondrial 16S ribosomal RNA region (MT-RNR2), and a near-identical nuclear-encoded form also exists. It was discovered in 2001 by Hashimoto and colleagues in Ikuo Nishimoto's lab at Keio University during a cDNA screen for factors that protected neurons from Alzheimer's-disease-related insults, and it is studied primarily as a cytoprotective and metabolic signaling peptide.

Vilon is a synthetic dipeptide, L-lysyl-L-glutamate (Lys-Glu), one of the short peptide bioregulators developed by Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology in Russia. It was designed as a minimal synthetic analogue reflecting active sequences found in thymic peptide preparations such as thymalin. Despite its very small size, it is promoted as a geroprotective and immunomodulatory agent. It is a research compound with no approved medical use.

Humanin acts both intracellularly and as a secreted, receptor-mediated factor. Intracellularly it binds and antagonizes the pro-apoptotic Bcl-2-family proteins BAX, tBID and BimEL, blocking their translocation to mitochondria and suppressing apoptosis. Extracellularly it signals through a tripartite cytokine-like receptor complex (CNTF receptor / WSX-1 / gp130) that activates STAT3, and also engages formyl-peptide receptors (FPRL1/FPR2). It modulates insulin/IGF-1 signaling, interacting with IGFBP-3 and enhancing AKT phosphorylation, and acts centrally in the hypothalamus as an insulin sensitizer; the engineered S14G analog (HNG) is far more potent than the native peptide in preclinical assays.

Vilon is hypothesized to act as a gene-regulating bioregulator: proponents propose that the dipeptide can penetrate cells, bind DNA and histones, and alter chromatin accessibility to switch on genes silenced with aging. In immune tissue it is reported to activate T-helper cells and modulate age-associated immune changes. Some microarray studies from the originating group describe changes in gene expression in mouse tissues after vilon exposure. As with other Khavinson peptides, these mechanistic claims rest mainly on the developing laboratory's own experiments rather than on independent confirmation.

The strongest data are preclinical. In cell and rodent models, humanin and HNG reduce neuronal death from amyloid-beta and other insults, shrink infarct size in stroke models, improve glucose handling, and reduce age-related cognitive decline in mice (Yen et al., Scientific Reports 2018; Hashimoto et al., J Neurosci 2001). Human evidence is observational, not interventional: circulating humanin declines with age, is lower in conditions such as Alzheimer's disease and the mitochondrial disorder MELAS, and higher levels have been associated with better "cognitive age" and with longevity-enriched cohorts (long-lived offspring, centenarians). Critically, there are no published randomized controlled trials of exogenous humanin or HNG in humans, and no completed published Phase 1 safety trial, so therapeutic benefit in people remains unproven and the human-versus-animal gap is large.

The vilon evidence base is almost entirely preclinical and comes from Vladimir Khavinson, Vladimir Anisimov and colleagues, published largely in Russian journals. Reported findings include inhibition of spontaneous and chemically induced tumors and increased lifespan in mice, plus effects on biological-age markers and gene expression. These are animal and cell studies from a single research tradition; there are essentially no independent Western randomized controlled trials or robust human efficacy data. To state it plainly: there are no human clinical trials of vilon in the mainstream indexed literature, so every claim about human benefit is an extrapolation from rodent and cell-culture work. The animal studies are typically conducted in inbred mouse strains at a single institution, with lifespan and tumor incidence as endpoints, without blinded pathology review, without preregistration, and without replication in a second laboratory using a different animal facility and diet, all of which are known to influence rodent lifespan results. The mechanistic work is similar in character: microarray and cell-culture studies attributing changes in gene expression to direct dipeptide interaction with DNA and histones, reported by the originating group and by a small number of collaborating laboratories, including studies of short peptides in stem cell differentiation and in monocyte and macrophage cell lines. The internal consistency of results within the group is notable, but the lack of external replication is a major limitation. Claims of anti-aging or immune benefit in humans should therefore be regarded as unproven. Compared with its siblings in the same Khavinson tradition, vilon sits at the least developed end: thymalin and cortexin at least have registered clinical use and observational human reports in Russia, and Cerebrolysin, an unrelated animal-tissue peptide preparation, has enough independent randomized trials to have been assessed twice by Cochrane. Vilon has none of that. There is no published modern toxicology dossier, no human pharmacokinetic data, and no regulatory dossier available for external review.

Because no controlled human trials of administered humanin or HNG have been completed and published, the human safety profile is essentially unknown, including immunogenicity, dosing tolerability, and long-term effects. As a STAT3-activating, anti-apoptotic and growth-signaling peptide, theoretical concerns include effects on cell survival and proliferation pathways, but these have not been characterized clinically. Material sold online as "humanin" is research-use-only chemical of unverified identity and purity, not a pharmaceutical product, adding contamination and mislabeling risks. No safety conclusions for human use can be drawn from the existing animal and cell data.

In the animal studies reported by its developers, vilon appears to be well tolerated at the doses tested, with low toxicity described. However, there is no meaningful independent human safety data, no long-term human studies, and no regulatory safety review outside its originating context. Because no human trial has been conducted, there is no adverse-event table to consult: statements that vilon is safe in people are assertions rather than findings. The absence of a published modern toxicology package is the specific gap that matters, since a regulator would expect repeat-dose toxicity in two species, genotoxicity testing, reproductive toxicity, local tolerance at the injection site, and immunogenicity assessment before any first-in-human study. None of that is available in the indexed literature. The identity and purity of material sold as vilon for research use are not guaranteed, and lyophilized vials distributed through research-chemical channels are not manufactured to pharmaceutical standards, are not tested for sterility or bacterial endotoxin, and may differ from the labeled peptide in content or purity. Injecting a non-sterile preparation carries the ordinary hazards of contamination, including local infection and systemic febrile reactions. A compound proposed to alter gene expression and immune cell behavior also warrants caution in anyone with a history of malignancy or autoimmune disease, a question that has never been addressed experimentally in humans. This is educational information only and not medical or dosing advice.

Humanin and its analog HNG are not approved by the FDA, EMA, or any major regulator for any indication; they are investigational/research-use-only compounds with no completed published Phase 1 human trial. They are not established WADA-prohibited substances by name, but exogenous peptides with growth-factor-like signaling can fall under broad anti-doping categories, so status should not be assumed.

Vilon is not approved as a drug by the US FDA, the European Medicines Agency, or other major Western regulators, and it is not a dietary supplement. It is sold and used only as a research chemical, and human clinical use is not sanctioned in the US.